CCA
IGMS

Catalyst Capital Advisors’s IGM Biosciences IGMS Stock Holding History

Catalyst Capital Advisors’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-250
Closed -$4K – 358
2019
Q3 		$4K Buy
+250
New +$5.05K ﹤0.01% 412

Other funds holding IGMS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Catalyst Capital Advisors's IGMS Position: Q4 2019 in Review

Catalyst Capital Advisors sold out of IGM Biosciences (IGMS) in Q4 2019, closing a stake of 250 shares — an estimated $4K sold.

Catalyst Capital Advisors first reported a position in IGMS in Q3 2019 and held it in 1 quarter. The position peaked at $4K in Q3 2019. 50 funds tracked by Wall St. Rank hold IGMS as of Q4 2019.

  • Catalyst Capital Advisors reported no remaining IGM Biosciences position as of Q4 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 250 IGM Biosciences shares in Q4 2019, an estimated $4K.
  • Catalyst Capital Advisors first reported a position in IGM Biosciences in Q3 2019 and held it in 1 quarter.
  • Catalyst Capital Advisors's IGM Biosciences position peaked at $4K in Q3 2019.
  • 50 funds tracked by Wall St. Rank held IGM Biosciences as of Q4 2019.

Based on Catalyst Capital Advisors's 13F filing for Q4 2019, filed 6 Feb 2020.